The content on this site is intended for healthcare professionals only
Dr Nikhil Khushalani talks to ecancer at ESMO 2026 about the primary analysis of the phase III HBI-8000-303 trial, evaluating the addition of the histone deacetylase (HDAC) inhibitor HBI-8000 to nivolumab in patients with unresectable or metastatic melanoma.
The study randomised 404 patients to receive HBI-8000 plus nivolumab or placebo plus nivolumab.
After a median follow-up of 37 months, the combination significantly improved median progression-free survival (11.7 versus 7.4 months; HR 0.73; p=0.0141) and achieved a higher objective response rate (41.4% versus 32.3%).
However, grade 3 or higher treatment-related adverse events were more frequent with the combination (55% versus 18%).
The findings suggest that HBI-8000 plus nivolumab offers a promising treatment option for patients with advanced melanoma who have not previously received anti-PD-(L)1 therapy, although increased toxicity remains an important consideration.
Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma
Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma
mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival
ASCO 2025: Importance of early testing in metastatic prostate cancer
Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
